Morepen laboratories ltd. has established a leadership position for its anti-asthmatic bulk drug Montelukast in the global market. As per the latest report by a global research firm-QYR Research, Morepen is the No.1 supplier globally in terms of total quantity sold, followed by Mylan and TAPI (Teva) who appear on the second and third position respectively.
CMD of Morepen laboratories ltd., Sushil Suri said that Morepen’s global sales for Montelukast Sodium stood at 16240 kg in calender year 2015, resulting in a market share of 23 per cent (approx.) compared to Mylan’s and Teva’s 12 per cent each. Aafter the company's board meeting, which discussed and took on record the 4th quarter and annual results of the firm for the financial year 2015-16.